First-line Herceptin monotherapy in metastatic breast cancer. - Wikidata - awgldk - TriplyDB

First-line Herceptin monotherapy in metastatic breast cancer.

First-line Herceptin monotherapy in metastatic breast cancer.

http://www.wikidata.org/entity/Q34100488

about

Trastuzumab-containing regimens for metastatic breast cancer Trastuzumab containing regimens for early breast cancer Trastuzumab containing regimens for early breast cancer Trastuzumab containing regimens for metastatic breast cancer ErbB2, EphrinB1, Src kinase and PTPN13 signaling complex regulates MAP kinase signaling in human cancers A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes IgE immunotherapy against cancer Nuclear T-STAR protein expression correlates with HER2 status, hormone receptor negativity and prolonged recurrence free survival in primary breast cancer and decreased cancer cell growth in vitro.VARS2 V552V variant as prognostic marker in patients with early breast cancer.CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient Generation of an enriched pool of DNA aptamers for an HER2-overexpressing cell line selected by Cell SELEX.Genetic instability favoring transversions associated with ErbB2-induced mammary tumorigenesis.Comprehensive copy number profiles of breast cancer cell model genomes.Ixabepilone as monotherapy or in combination with capecitabine for the treatment of advanced breast cancer.Detection of HER2 amplification in circulating free DNA in patients with breast cancer.An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer.Genetic advances will influence the practice of medicine: examples from cancer research and care of cancer patients.Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials.Can maintenance trastuzumab be stopped in patients with HER2-positive metastatic breast cancer?Analysis of HER2 gene amplification using an automated fluorescence in situ hybridization signal enumeration system.Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations.Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab.Phytoestrogens: perpetrators or protectors?Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies.A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment.Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer.Current and Emerging Treatment Regimens for HER2-Positive Breast Cancer Kinoids: a family of immunogens for active anticytokine immunotherapy applied to autoimmune diseases and cancer.Kinase dysfunction and kinase inhibitors.Systemic treatment of HER2-positive metastatic breast cancer: a systematic review.The role of ctDNA detection and the potential of the liquid biopsy for breast cancer monitoring.Adaptive immunity programmes in breast cancer.Trastuzumab cardiotoxicity: from clinical trials to experimental studies.The cost-effectiveness issue of adjuvant trastuzumab in early breast cancer.HER2 signaling downregulation by trastuzumab and suppression of the PI3K/Akt pathway: an unexpected effect on TRAIL-induced apoptosis.Marked radiographic response of a HER-2-overexpressing biliary cancer to trastuzumab.Expression of asialoglycoprotein receptor 1 in human hepatocellular carcinoma Deciphering the Correlation between Breast Tumor Samples and Cell Lines by Integrating Copy Number Changes and Gene Expression Profiles.

P2860

Q24194019-047FE0B5-69BA-4C35-92BA-FBEEE6957B44 Q24200192-EDECD3AB-8661-4C29-8EA9-BEA79FF2426E Q24244420-E69740B2-6068-4AFE-B5B8-2124ACDF06BB Q24244565-0B4D4F40-C867-4706-9830-7D9C8DA2A6E1 Q24303562-E28F7F39-C87A-4201-8921-22C054B80999 Q24647928-656D5CBF-B62B-42F0-974F-6841DF423FFF Q28081223-51C949A7-8071-4AA7-81F1-A3025D542557 Q30009589-B688993C-841F-4D57-98A8-3E224F5A3BB7 Q33587746-1C99DE68-9857-4533-9479-C600AD267418 Q33728102-A40B14CD-39A6-409D-8DDA-0D5B408569B1 Q33991887-33C280D5-44E5-401C-823B-3DA18D0C7338 Q34020212-2A8B2E0F-D1BB-4744-9872-DADA6AD70EBB Q34480698-21C0C00C-F8F3-4946-9452-B160A3E9AE7C Q34788890-120DC0DF-20A1-400F-B943-76A22A51FCE5 Q34806810-8CF6841E-7E90-4DA5-A652-2B0975AA17FE Q34994161-1CA1A602-AE55-47D3-9E2B-5E0F7DC3E46E Q35051949-035BF012-5428-4059-A8B9-B2612D6D39AD Q35624010-8ACF2C37-9901-4A44-AEEF-042C85DD15BE Q35699689-1E51440E-B194-4514-AD78-4DCB09E2D82D Q35789621-77D5F7CF-BE6E-44F1-9CBF-AC788EC65FEB Q35891822-94AE5065-5226-45D8-91F6-E8DAD5EB095B Q36644476-DAD15A78-8843-4B1C-83D4-1D58FE7AD0B7 Q36671182-1416344A-5B24-4EB6-9AEE-8B591C207A54 Q36693285-3E29EA89-088E-4364-B1C1-19A5EB074E4B Q36839782-FB141BF7-9DB5-457C-AAFD-4AE1403FF7C9 Q36923104-ED8A0154-5FAA-4CA6-BFC2-4DDEEC3BE775 Q37411548-67D18C08-B1BB-4B3A-B13E-D09A40F4BE13 Q37678070-D2FB1303-BBA9-4C91-B3C0-979AE190DE18 Q37733237-CC015C7A-DCE4-4923-B731-FD22E0DDFB53 Q37773243-170088E2-3C5B-4FA1-B6E8-F21816F5BCBE Q38075152-36927077-9BFE-4E63-9F6A-ABD6BDF419E3 Q38209463-A590434C-9564-45F0-9076-C9AFC63584BC Q38825179-6D0DD1E9-3DF6-4D43-89A6-782C97514280 Q38937896-47F1F11E-F90B-4F24-B7C3-EC7D8D041E4D Q38974785-E935F504-4F0C-4861-AC41-EBFDC320DE97 Q40303131-CC25DEED-FF61-4405-8D82-110591218E94 Q40397252-5D8D797E-DDA4-4E5F-982A-E11C468DF631 Q42033747-72D2CBD5-7946-403A-B635-556E9B8BBC57 Q42060938-E8857BA3-F793-45A4-8FF4-DD8D21395DF7 Q42428131-2E791643-2313-4D04-8272-CF8632625F0A

P2860

First-line Herceptin monotherapy in metastatic breast cancer.

http://www.wikidata.org/entity/Q34100488

description

2001 nî lūn-bûn

@nan

2001 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

First-line Herceptin monotherapy in metastatic breast cancer.

@ast

First-line Herceptin monotherapy in metastatic breast cancer.

@en

First-line Herceptin monotherapy in metastatic breast cancer.

@nl

type

label

First-line Herceptin monotherapy in metastatic breast cancer.

@ast

First-line Herceptin monotherapy in metastatic breast cancer.

@en

First-line Herceptin monotherapy in metastatic breast cancer.

@nl

prefLabel

First-line Herceptin monotherapy in metastatic breast cancer.

@ast

First-line Herceptin monotherapy in metastatic breast cancer.

@en

First-line Herceptin monotherapy in metastatic breast cancer.

@nl

P1433

Q34100488-78994B0D-0E81-4F0A-84BE-2B56C5672597

P1476

Q34100488-4668ACFB-63D7-4823-AB82-56C25F5A85B0

P2093

Q34100488-079E11B4-71A1-49F7-BD3B-47582133DE9C

Q34100488-123DD67F-E1C5-4B35-9895-448421CBE3D6

Q34100488-1D0F3553-F6BE-4D43-B405-A86509514411

Q34100488-1DF957F4-A031-495A-8BD7-4DA726561A00

Q34100488-20ABE11C-16C6-43F1-9A02-6ABDE0C807C7

Q34100488-26BFA0B4-4406-4FD6-92CF-AA5FD245905D

Q34100488-364ACB33-35FB-4594-8379-F6881F76407A

Q34100488-47ADA50E-1BBC-4005-B586-22A834846E15

Q34100488-4A521524-C906-4F92-B80E-73E2E8A9E1E4

Q34100488-5F4ED02D-DD50-404D-8A68-901AA7AFAF9C

P304

Q34100488-7484A6EC-DDD6-4ABB-981E-8C3529EAF636

P31

Q34100488-FA94B321-D77C-409B-83BE-F94B148CF219

P356

Q34100488-2D3BC74B-F2DE-4E12-8171-6E63C41ACB14

P478

Q34100488-CA7F86F5-B3A2-4BB4-9B7A-D1ED72C840BA

P577

Q34100488-A2E55112-B4CE-45C6-AAFC-82F62F921BDB

P698

Q34100488-8671CDFB-273F-4275-99FB-2E725C86B9B3

P356

P1433

P1476

First-line Herceptin monotherapy in metastatic breast cancer.

@en

P2093

C L Vogel

http://www.w3.org/2001/XMLSchema#string

D J Slamon

http://www.w3.org/2001/XMLSchema#string

D Tripathy

http://www.w3.org/2001/XMLSchema#string

J C Gutheil

http://www.w3.org/2001/XMLSchema#string

L Fehrenbacher

http://www.w3.org/2001/XMLSchema#string

L N Harris

http://www.w3.org/2001/XMLSchema#string

M A Cobleigh

http://www.w3.org/2001/XMLSchema#string

M Burchmore

http://www.w3.org/2001/XMLSchema#string

M Murphy

http://www.w3.org/2001/XMLSchema#string

S J Stewart

http://www.w3.org/2001/XMLSchema#string

P304

37-42

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000055400

http://www.w3.org/2001/XMLSchema#string

P478

61 Suppl 2

http://www.w3.org/2001/XMLSchema#string

P577

2001-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11694786

http://www.w3.org/2001/XMLSchema#string